202 related articles for article (PubMed ID: 28281554)
1. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA; Medeiros LJ; Fang L; Shah JJ; Weber DM; Thomas SK; Manasanch EE; Hao S; Shen Q; Orlowski RZ; Lin P; Lu X
Mod Pathol; 2017 Jun; 30(6):843-853. PubMed ID: 28281554
[TBL] [Abstract][Full Text] [Related]
2. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
3. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
4. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis.
Barilà G; Bonaldi L; Grassi A; Martines A; Liço A; Macrì N; Nalio S; Pavan L; Berno T; Branca A; Calabretto G; Carrino M; Teramo A; Manni S; Piazza F; Semenzato G; Zambello R
Blood Cancer J; 2020 Feb; 10(2):18. PubMed ID: 32066724
[No Abstract] [Full Text] [Related]
5. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
[TBL] [Abstract][Full Text] [Related]
6. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
[TBL] [Abstract][Full Text] [Related]
7. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
[TBL] [Abstract][Full Text] [Related]
8. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
9. Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.
Lange K; Gadzicki D; Schlegelberger B; Göhring G
Leuk Res; 2010 Aug; 34(8):1002-6. PubMed ID: 20022374
[TBL] [Abstract][Full Text] [Related]
10. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.
Mohamed AN; Bentley G; Bonnett ML; Zonder J; Al-Katib A
Am J Hematol; 2007 Dec; 82(12):1080-7. PubMed ID: 17654686
[TBL] [Abstract][Full Text] [Related]
11. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.
Lim AS; Lim TH; See KH; Ng YJ; Tan YM; Choo NS; Lim SX; Yee Y; Lau LC; Tien SL; Sathish K; Tan DC
Chin Med J (Engl); 2013; 126(10):1872-7. PubMed ID: 23673102
[TBL] [Abstract][Full Text] [Related]
13. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.
Soekojo CY; Wang GM; Chen Y; Casan J; Wolyncewicz G; Lin A; Poon LM; de Mel S; Koh LP; Tan LK; Ooi MG; Nagarajan C; Liu Y; Lai YY; Huang XJ; Spencer A; Gopalakrishnan SK; Lu J; Chng WJ
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e470-e477. PubMed ID: 31171473
[TBL] [Abstract][Full Text] [Related]
14. Hypodiploidy is a major prognostic factor in multiple myeloma.
Smadja NV; Bastard C; Brigaudeau C; Leroux D; Fruchart C;
Blood; 2001 Oct; 98(7):2229-38. PubMed ID: 11568011
[TBL] [Abstract][Full Text] [Related]
15. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.
Van Wier S; Braggio E; Baker A; Ahmann G; Levy J; Carpten JD; Fonseca R
Haematologica; 2013 Oct; 98(10):1586-92. PubMed ID: 23716545
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
17. Karyotypic abnormalities and their clinical aspects in multiple myeloma.
Scudla V; Jarosová M; Kapustová M; Indrák K; Smoldas J
Acta Univ Palacki Olomuc Fac Med; 1991; 129():69-79. PubMed ID: 1837676
[TBL] [Abstract][Full Text] [Related]
18. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a cytogenetically complex Chinese multiple myeloma-derived cell line with homozygous p53 deletion and cyclin E overexpression.
Cheng SH; Ng MH; Tsang KS; Lau KM; Chan JC; Liu HS; Chu RW; Poon CS; Ng HK
Int J Oncol; 2004 May; 24(5):1141-8. PubMed ID: 15067335
[TBL] [Abstract][Full Text] [Related]
20. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma.
Yoshida T; Ri M; Fujinami H; Oshima Y; Tachita T; Marumo Y; Sasaki H; Kinoshita S; Totani H; Narita T; Masaki A; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
Int J Hematol; 2019 Aug; 110(2):228-236. PubMed ID: 31119611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
